左卡尼汀在血液透析贫血患者中的应用观察  

Application observation of levocarnitine on anemia in hemodialysis patients

作　　者：许雁集[1] 徐树人[1] 于颖吉[1] 

机构地区：[1]上海市第二人民医院肾内科,上海200011

出　　处：《中国当代医药》2013年第6期83-84,86,共3页China Modern Medicine

摘　　要：目的观察维持性血液透析患者在应用重组促红细胞生成素治疗6个月后,贫血仍未达到靶目标值,继而联合应用左卡尼汀的治疗效果。方法将34例维持性血液透析患者随机分为两组,每组各17例。两组均应用重组促红细胞生成素3000U,每周2次,皮下注射。治疗组每次血液透析后予左卡尼汀0.5g静脉注射,对照组静脉注射等量0.9%氯化钠溶液。疗程为12周。观察两组患者治疗前后血红细胞、血红蛋白、血细胞比容、血浆清蛋白的情况。结果治疗组患者红细胞、血红蛋白、血细胞比容、血浆清蛋白上升水平高于对照组(P<0.05)。结论左卡尼汀能显著提高重组促红细胞生成素对维持性血液透析患者贫血治疗的效果,可以改善维持性血液透析患者营养状况。Objective To observe the therapy effect of levocarnitine in maintenance hemodialysis patients whose anemia have not reached the target value after the application of recombinant erythropoietin treatment six months. Methods Thirty-four cases of hemodialysis patients were randomly divided into 2 groups, 17 cases in each group. The two groups were given the application of recombinant erythropoietin 3 000 U, 2 times per week, subcutaneous injection. The treatment group were used levocarnitine 0.5 g, intravenous injection after each hemodialysis, control group were given intravenous saline. Treatment course was 12 weeks. Two groups of patients before and after treatment of red blood cell, hemoglobin, hematocrit, plasma albumin were observed. Results The treatment group patients erythrocyte, hemoglobin, hematocrit, plasma albumin increased level were higher than those of control group （P 〈 0.05）. Conclusion Levocamitine can significantly increase the effect of recombinant erythropoietin on anemia in hemodialysis patients, can improve the nutritional status of maintenance hemodialysis patients.

关 键 词：左卡尼汀 血液透析 贫血 观察 

分 类 号：R973[医药卫生—药品]